Cargando…

Pharmacologic Control of CAR T Cells

Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors. However, despit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caulier, Benjamin, Enserink, Jorrit M., Wälchli, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122276/ https://www.ncbi.nlm.nih.gov/pubmed/33919245 http://dx.doi.org/10.3390/ijms22094320

Ejemplares similares

How CAR T Cells Breathe
por: Forcados, Christopher, et al.
Publicado: (2022)

Determination of CAR T cell metabolism in an optimized protocol
por: Joaquina, Sandy, et al.
Publicado: (2023)

Metabolic pathways further increase the complexity of cell size control in budding yeast
por: Enserink, Jorrit M.
Publicado: (2014)

An overview of Cdk1-controlled targets and processes
por: Enserink, Jorrit M, et al.
Publicado: (2010)

Sumo and the cellular stress response
por: Enserink, Jorrit M.
Publicado: (2015)

Chemical Genetics: Budding Yeast as a Platform for Drug Discovery and Mapping of Genetic Pathways
por: Enserink, Jorrit M.
Publicado: (2012)

Cell Cycle-Dependent Transcription: The Cyclin Dependent Kinase Cdk1 Is a Direct Regulator of Basal Transcription Machineries
por: Enserink, Jorrit M., et al.
Publicado: (2022)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments
por: Rønneberg, Leiv, et al.
Publicado: (2021)

Combinatorial CAR design improves target restriction
por: Köksal, Hakan, et al.
Publicado: (2020)

P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA
por: Kusowska, Aleksandra, et al.
Publicado: (2023)

Colorectal cysts as a validating tool for CAR therapy
por: Dillard, Pierre, et al.
Publicado: (2020)

Checkpoint proteins control morphogenetic events during DNA replication stress in Saccharomyces cerevisiae
por: Enserink, Jorrit M., et al.
Publicado: (2006)

Analysis of the pheromone signaling pathway by RT-qPCR in the budding yeast Saccharomyces cerevisiae
por: Ramos-Alonso, Lucía, et al.
Publicado: (2022)

Deconvolution of clinical variance in CAR-T cell pharmacology and response
por: Kirouac, Daniel C., et al.
Publicado: (2023)

Cdc28/Cdk1 positively and negatively affects genome stability in S. cerevisiae
por: Enserink, Jorrit M., et al.
Publicado: (2009)

Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
por: Moghanloo, Ehsan, et al.
Publicado: (2021)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Centromeres License the Mitotic Condensation of Yeast Chromosome Arms
por: Kruitwagen, Tom, et al.
Publicado: (2018)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Long-term surviving cancer patients as a source of therapeutic TCR
por: Inderberg, Else Marit, et al.
Publicado: (2020)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Mapping the Synthetic Dosage Lethality Network of CDK1/CDC28
por: Zimmermann, Christine, et al.
Publicado: (2017)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response
por: Kirouac, Daniel C., et al.
Publicado: (2023)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
por: Kast, Johannes, et al.
Publicado: (2022)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

Cdk1 gates cell cycle-dependent tRNA synthesis by regulating RNA polymerase III activity
por: Herrera, Maria C, et al.
Publicado: (2018)

Cdk1 gates cell cycle-dependent tRNA synthesis by regulating RNA polymerase III activity
por: Herrera, Maria C, et al.
Publicado: (2018)

CELLULAR, A Cell Autophagy Imaging Dataset
por: Al Outa, Amani, et al.
Publicado: (2023)

Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
por: Kath, Jonas, et al.
Publicado: (2022)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β(2)-adrenergic receptor
por: Rangarajan, Savithri, et al.
Publicado: (2003)

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective
por: Qi, Xingxing, et al.
Publicado: (2023)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Improving CAR T-Cell Persistence
por: Pietrobon, Violena, et al.
Publicado: (2021)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k5c279tu290kev113o4cbpedp8